EICHORCondition: IgA Nephropathy · Sponsor: RemeGen Co., Ltd.
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Remegen Site #5 | Los Angeles, California, United States | — |
| Remegen Site #13 | Los Angeles, California, United States | — |
| Remegen Site #14 | Los Angeles, California, United States | — |
| Remegen Site #10 | Sacramento, California, United States | — |
| Remegen Site #8 | San Francisco, California, United States | — |
| Remegen Site #16 | Fort Lauderdale, Florida, United States | — |
| Remegen Site #17 | Augusta, Georgia, United States | — |
| Remegen Site #2 | Philadelphia, Pennsylvania, United States | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04905212